ANVS

1.22

3.17% -0.04

Dopo l'orario di chiusura: 1.22

Annovis Bio Inc (ANVS)

Panoramica Notizia Cronologia dei prezzi Perché ANVS Giù? Forum Previsione

Precedente Chiudi:

$1.26

Aprire:

$1.24

Volume 24 ore:

73,582

Relative Volume:

0.18

Capitalizzazione di mercato:

$24.16M

Reddito:

Utile/perdita netta:

$-40.94M

Rapporto P/E:

-0.3177

EPS:

-3.84

Flusso di cassa netto:

$-22.97M

1 W Prestazione:

-4.69%

1M Prestazione:

-36.79%

6M Prestazione:

-85.91%

1 anno Prestazione:

-86.43%

Intervallo 1D:

$1.19

$1.27

Intervallo di 1 settimana:

$1.17

$1.35

Portata 52W:

$1.11

$20.00

Annovis Bio Inc Stock (ANVS) Company Profile

Nome

Annovis Bio Inc

Settore

Healthcare (1151)

Industria

Biotechnology (660)

Telefono

484-875-3192

Indirizzo

101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA

Dipendente

Cinguettio

Prossima data di guadagno

2024-12-11

Ultimi documenti SEC

ANVS's Discussions on Twitter

Confronta ANVS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ANVS Annovis Bio Inc	1.22	24.16M	0	-40.94M	-22.97M	-3.84
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-02-10	Downgrade	D. Boral Capital	Buy → Hold
2024-10-25	Aggiornamento	Maxim Group	Hold → Buy
2023-12-29	Iniziato	Canaccord Genuity	Buy
2021-07-07	Reiterato	Maxim Group	Buy

Annovis Bio Inc Borsa (ANVS) Ultime notizie

Apr 09, 2025

Annovis Bio stock plunges to 52-week low of $1.14 By Investing.com - Investing.com Canada

Apr 09, 2025

Annovis Bio stock plunges to 52-week low of $1.14 - Investing.com

Apr 09, 2025

Buntanetap shows early potential for Parkinson’s-related dementia - The Pharma Letter

Apr 09, 2025

Apr 08, 2025

Parkinson's Disease Pipeline Analysis and Clinical Trials - openPR.com

Apr 08, 2025

Apr 02, 2025

Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MSN

Apr 02, 2025

Mar 31, 2025

Annovis Bio stock hits 52-week low at $1.52 amid sharp decline By Investing.com - Investing.com South Africa

Mar 31, 2025

Annovis Bio stock hits 52-week low at $1.52 amid sharp decline - Investing.com India

Mar 31, 2025

Annovis Bio Receives Non-Compliance Notice from NYSE - MSN

Mar 31, 2025

Mar 30, 2025

Annovis Bio to Present Promising Data on Buntanetap at AD/PD™ 2025 - MSN

Mar 30, 2025

Mar 27, 2025

Annovis Bio faces NYSE delisting over market cap, equity shortfall By Investing.com - Investing.com South Africa

Mar 27, 2025

Annovis Bio Gets NYSE Noncompliance Notice - MarketScreener

Mar 27, 2025

Annovis Bio Faces NYSE Non-Compliance Notice - TipRanks

Mar 27, 2025

Annovis Bio faces NYSE delisting over market cap, equity shortfall - Investing.com

Mar 27, 2025

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE - GlobeNewswire

Mar 27, 2025

NYSE Warning: Annovis Bio Must Submit 45-Day Survival Plan as Market Cap Plunges - Stock Titan

Mar 27, 2025

Mar 26, 2025

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program - GlobeNewswire

Mar 26, 2025

Mar 25, 2025

Stocks In Spotlight: ANVS, PTN, AVIR, IRWD, FGEN, ACAD - RTTNews

Mar 25, 2025

Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MSN

Mar 25, 2025

Agitation in Alzheimer's Disease Market: Analysis - openPR.com

Mar 25, 2025

Annovis Bio Inc. to Present Key Findings at AD/PD™ 2025 Conference in Vienna on Alzheimer's and Parkinson's Treatments - Nasdaq

Mar 25, 2025

Game-Changing Phase 3 Results: Annovis Reveals Dual Breakthrough in Parkinson's and Alzheimer's Treatment - Stock Titan

Mar 25, 2025

Mar 21, 2025